Yahoo · Nov 4, 2026
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it would present three posters on its research on the role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of Myeloid-Derived Suppressor Cells (MDSCs) at the upcoming 68th American Society of Hematology (ASH) Annual Meeting and Exposition taking place on Decembe

